Serena Williams Is Back — And She's Bringing GLP-1s With Her
When Serena Williams announced her retirement from professional tennis in 2022, the sports world mourned the end of an era. The greatest women's tennis player of all time, a 23-time Grand Slam champion, was stepping away. But as of June 2025, the GOAT is bounding back onto the court — and this time, she's bringing a very modern secret weapon with her: GLP-1 therapy.
Williams, now 44 years old, confirmed she would be returning to professional competition for a wild card doubles match in London during the week of June 8. The announcement sent shockwaves through the tennis world, but for a growing community of biohackers, longevity enthusiasts, and what the internet affectionately calls "peptide bros," the news felt like a massive validation of everything they've been saying for years.
What Is GLP-1 and Why Does It Matter for Athletes?
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that regulates blood sugar, appetite, and digestion. GLP-1 receptor agonists — the drug class that includes household names like Ozempic, Wegovy, and Zepbound — mimic this hormone to help people lose weight, control hunger, and stabilize glucose levels.
Originally developed to treat type 2 diabetes, these medications have exploded in popularity over the past few years as a weight-loss tool for the general public. But what many people don't fully appreciate is the downstream effect that significant, sustained weight loss can have on physical performance — especially joint health, mobility, and cardiovascular efficiency.
This is precisely what Serena Williams has been talking about publicly. In a Super Bowl advertisement for Ro, a telehealth company that prescribes GLP-1 medications like Ozempic, Wegovy, and Zepbound, Williams said plainly: "I'm moving better on Ro." She described improved mobility, steadier blood sugar levels throughout the day, and an overall feeling of being "healthier" during training sessions. Her husband, Reddit co-founder Alexis Ohanian, sits on the board of Ro and is a significant investor in the company.
The Knee Connection: How Weight Loss Can Restore Athletic Performance
One of the most significant details Williams has shared is how much better her knees feel at her new, lower body weight. This isn't anecdotal fluff — it's backed by biomechanics. Studies have long shown that for every pound of body weight lost, the force exerted on the knee joint during activities like running and lateral movement decreases by roughly four pounds.
For a professional tennis player whose knees have endured decades of explosive starts, stops, and direction changes on hard courts, this kind of reduction in joint load is not trivial. It's transformative. Williams has previously dealt with knee injuries and health complications following childbirth, making her return to court all the more remarkable.
The fact that GLP-1 therapy played a role in helping her shed weight and restore that joint comfort is something the peptide community has been quick to highlight. If a 44-year-old woman — even one as genetically gifted and disciplined as Serena Williams — can use GLP-1 therapy to recapture athletic function, the implications for recreational athletes and aging adults are enormous.
Why the Peptide Community Is Buzzing
The so-called "peptide bro" community — a loosely defined group of fitness enthusiasts, biohackers, and longevity-focused individuals who use various peptides and compounds to optimize their health and physical performance — has followed Serena's story with keen interest. GLP-1 agonists sit at the intersection of mainstream medicine and performance optimization, and Williams' public endorsement adds enormous cultural weight to a trend that has been building in wellness circles for years.
Beyond GLP-1s specifically, her return raises broader questions about what modern peptide science can do for aging athletes. Researchers and enthusiasts alike are exploring compounds that support muscle retention, joint repair, inflammation reduction, and metabolic health. Some of the most discussed include:
- BPC-157: A body-protective compound studied for its potential to accelerate tissue and tendon repair, commonly discussed in athletic recovery contexts.
- TB-500 (Thymosin Beta-4): Another peptide popular in recovery discussions, believed by some researchers to support wound healing and reduce inflammation.
- Ipamorelin and CJC-1295: Growth hormone-releasing peptides that are often discussed in the context of body composition, muscle mass, and recovery in older adults.
- GLP-1 receptor agonists: Now the most mainstream of all, bridging the gap between clinical medicine and the performance optimization world.
Williams' comeback doesn't just validate GLP-1s — it validates the broader idea that targeted pharmacological and biological interventions can meaningfully extend athletic careers and physical capability well into one's forties and beyond.
The Longevity Angle: Age Is Just a Number (With the Right Tools)
Perhaps the most profound aspect of Serena's comeback is what it signals about the future of human performance and aging. The longevity science field has grown rapidly in recent years, with researchers exploring everything from NAD+ precursors and senolytics to advanced hormone optimization and peptide therapies. The central premise is simple: aging is not just inevitable decline, but a biological process that can be modulated.
Williams at 44 returning to professional tennis — any level of professional tennis — forces a cultural reassessment of what "too old" means for elite sport. And when she attributes part of her improved physical state to GLP-1 therapy, it's a real-world case study that no longevity researcher could have scripted better.
For the peptide and biohacking community, this is the kind of high-profile, public proof of concept that moves conversations from niche forums into mainstream discourse. When the greatest tennis player of all time says a peptide-adjacent therapy helped her move better and feel healthier, people listen.
What This Means for the Average Person
Williams' story is not just for professional athletes or wealthy biohackers. The growing accessibility of GLP-1 medications through telehealth platforms has made these therapies available to a wider population than ever before. For everyday people dealing with excess weight, joint pain, or metabolic issues that are limiting their physical activity and quality of life, her experience offers a relatable and inspiring narrative.
The key takeaway is not that GLP-1s are a magic bullet. They are a tool — a powerful one — that, when combined with proper nutrition, training, and recovery protocols, can help people reclaim physical function they thought was lost to time. Serena Williams is proof that with the right support, the body can still perform at extraordinary levels far beyond what previous generations might have considered possible.
Looking Ahead: A New Chapter in Sports and Performance Science
As Williams steps back onto the professional court, all eyes will be watching — not just to see whether she wins, but to understand how she performs physically. Every sprint, every serve, every lateral movement will be examined as evidence of what GLP-1-assisted training can produce in a middle-aged body that has been pushed to its absolute limits over a legendary career.
Whether or not her doubles comeback leads to more competitive play, Serena Williams has already done something significant: she has placed GLP-1 therapy and the broader conversation about peptides and longevity science squarely in the center of mainstream sports culture. For the peptide bros, the biohackers, and the longevity researchers, that's a victory in itself.